  Quantum computing, with its superior computational capabilities compared to
classical approaches, holds the potential to revolutionize numerous scientific
domains, including pharmaceuticals. However, the application of quantum
computing for drug discovery has primarily been limited to proof-of-concept
studies, which often fail to capture the intricacies of real-world drug
development challenges. In this study, we diverge from conventional
investigations by developing \rev{a hybrid} quantum computing pipeline tailored
to address genuine drug design problems. Our approach underscores the
application of quantum computation in drug discovery and propels it towards
more scalable system. We specifically construct our versatile quantum computing
pipeline to address two critical tasks in drug discovery: the precise
determination of Gibbs free energy profiles for prodrug activation involving
covalent bond cleavage, and the accurate simulation of covalent bond
interactions. This work serves as a pioneering effort in benchmarking quantum
computing against veritable scenarios encountered in drug design, especially
the covalent bonding issue present in both of the case studies, thereby
transitioning from theoretical models to tangible applications. Our results
demonstrate the potential of a quantum computing pipeline for integration into
real world drug design workflows.
